More MS news articles for December 2000

Pathobiotek Reports 'Notice of Allowability' For the Patent On the Intellectual Property of the MS Project

http://www.thescientist.com/yr2000/nov/research_001127.html

December 12, 2000

HOUSTON--(BUSINESS WIRE)--Dec. 11, 2000 via NewsEdge Corporation -

Pathobiotek Diagnostics Inc. (OTCBB:PBTK) (http://www.pathobiotek.com), a developer of products for the diagnosis and evaluation of treatment for multiple sclerosis (MS) and other immune disorders, announced the "Certificate of Allowability" for a patent. The actual issuance of the patent is now a formality, which will occur soon after the required formal paperwork is returned to the patent office.

The technology encompasses tests for a bacterium discovered by scientists at Pathobiotek and that organism appears to correlate with symptoms of MS. The company's investigations have demonstrated that the organism can be identified and quantified from blood samples. The resulting intellectual property is the basis for licensing agreements and subsequent revenues.

The commercial value of this patent has enormous upside potential and could be of significant financial benefit to Pathobiotek. It is expected that the revenues committed for the 4th quarter will result in the first profitable quarter this year.

Additional information on Pathobiotek Diagnostics Inc. can be obtained at http://www.pathobiotek.com.

Safe Harbor for Forward-Looking Statements: Except for historical information contained herein, the statements in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the company's actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product price volatility, product demand, market competition, risk inherent in the company's domestic and international operations, imprecision in estimating product reserves and the company's ability to replace and expand its holdings.

CONTACT: Pathobiotek Diagnostics Inc., Houston | Investor Relations: | Glinda Fortner, 281/364-6054 Ext. 7065 | Fax: 281/364-6053 | www.pathobiotek.com